We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

LPL Receptor

Lysophospholipid (LPL) receptor modulators here act mainly on sphingosine-1-phosphate (S1P) signaling. Lysophospholipid receptors are G protein-coupled receptors for lysophosphatidic acid (LPA) and S1P. A 2010 nomenclature review listed five LPA receptors with a proposed sixth (LPA1 to LPA6) and five S1P receptors. Ceralifimod, S1P1 agonist 1 and (S)-FTY720-phosphonate are agonists at S1P receptor 1, which controls lymphocyte exit from lymphoid organs. Other compounds change the amount of ligand available to the receptors. SLF1081851 and SLF80821178 inhibit spinster homolog 2 (Spns2), a transporter that exports S1P from cells. Spns2 was identified in 2009 as a sphingolipid transporter needed for migration of zebrafish myocardial precursors. S1PL-IN-1 inhibits S1P lyase, the enzyme that degrades S1P irreversibly inside cells.

1 Item

  • Ibrolipim
    Cat. No.
    A75874
    CAS No.
    133208-93-2

    Ibrolipim

    Synonyms: NO-1886

    Ibrolipim is an orally active lipoprotein lipase (LPL) activator that effectively decreases plasma triglyceride levels while promoting an increase in high-density lipoprotein cholesterol. Its biological activity includes renoprotective and hypolipidemic effects, making it a valuable tool for research into metabolic disorders and cardiovascular health. Ibrolipim is utilized in studies exploring lipid metabolism and its implications for diseases associated with dyslipidemia.

    In stock View Details
    5 mg
    $35.00
    10 mg
    $50.00
    All 6 sizes

1 Item

Added to your cart

View Cart Checkout

    Loading...